-
公开(公告)号：US20200339540A1
公开(公告)日：2020-10-29
申请号：US16924346
申请日：2020-07-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xiang-Yang Ye , Christian L. Morales , Mendi A. Higgins , Eric Mull
IPC: C07D401/14 , A61P35/00 , C07D471/04 , C07D498/04
Abstract: The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
公开(公告)号：US10745384B2
公开(公告)日：2020-08-18
申请号：US16347831
申请日：2017-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xiang-Yang Ye , Christian L. Morales , Mendi A. Higgins , Eric Mull
IPC: C07D401/14 , A61P35/00 , C07D471/04 , C07D498/04 , A61K31/404
Abstract: The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
公开(公告)号：US10358463B2
公开(公告)日：2019-07-23
申请号：US15475227
申请日：2017-03-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Martin Patrick Allen , Ling Li , Michael S. Bowsher , Eric P. Gillis , Eric Mull , Qian Zhao , Li-Qiang Sun , David R. Langley , Paul Michael Scola
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US09598433B2
公开(公告)日：2017-03-21
申请号：US14435047
申请日：2013-10-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Li-Qiang Sun , Eric P. Gillis , Eric Mull , Michael S. Bowsher , Qian Zhao , Paul Michael Scola
IPC: C07D498/04 , C07K5/083 , A61K38/20 , A61K38/21 , A61K31/4725 , A61K31/4741 , A61K31/498 , A61K45/06 , C07D519/00
CPC classification number: C07D498/04 , A61K31/4725 , A61K31/4741 , A61K31/498 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/212 , A61K45/06 , C07D519/00 , C07K5/081 , A61K2300/00
Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
-
公开(公告)号：US20160137696A1
公开(公告)日：2016-05-19
申请号：US14938327
申请日：2015-11-11
Applicant: Bristol-Myers Squibb Company
Inventor： Kevin W. Gillman , Jason Goodrich , Kenneth M. Boy , Yunhui Zhang , Claudio Mapelli , Michael A. Poss , Li-Qiang Sun , Qian Zhao , Eric Mull , Eric P. Gillis , Paul Michael Scola
CPC classification number: C07K7/08 , A61K38/00 , A61K38/10 , A61K45/06 , A61K51/088 , C07K7/56 , Y02A50/463
Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Abstract translation: 本公开提供了作为免疫调节剂的化合物，因此可用于改善各种疾病，包括癌症和感染性疾病。
-
Patent Agency Ranking
6.发明申请MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS 有权PD-1 / PD-L1和CD80（B7-1）/ PD-L1蛋白/蛋白质相互作用的MACROCYCLIC抑制剂公开(公告)号：US20140294898A1
公开(公告)日：2014-10-02
申请号：US14201977
申请日：2014-03-10
Applicant: Bristol-Myers Squibb Company
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Abstract translation: 本公开提供了抑制PD-1 / PD-L1和PD-L1 / CD80蛋白/蛋白相互作用的新型大环肽，因此可用于改善各种疾病，包括癌症和感染性疾病。
-
公开(公告)号：US10745382B2
公开(公告)日：2020-08-18
申请号：US15290167
申请日：2016-10-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Kap-Sun Yeung , Timothy P. Connolly , David B. Frennesson , Katharine A. Grant-Young , Piyasena Hewawasam , David R. Langley , Zhaoxing Meng , Eric Mull , Kyle E. Parcella , Mark George Saulnier , Li-Qiang Sun , Alan Xiangdong Wang , Ningning Xu , Juliang Zhu , Paul Michael Scola
IPC: C07D401/14 , C07D213/71 , C07D455/02 , A61K31/135 , A61K31/138 , A61K31/166 , A61K31/397 , A61K31/40 , A61K31/4025 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4453 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5375 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C215/20 , C07C235/46 , C07D205/04 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/22 , C07D213/80 , C07D213/82 , C07D213/85 , C07D265/30 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D491/08
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US09944678B2
公开(公告)日：2018-04-17
申请号：US14971352
申请日：2015-12-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Li-Qiang Sun , Qian Zhao , Eric P. Gillis , Michael Matthew Miller , Martin Patrick Allen , Eric Mull , Paul Michael Scola
CPC classification number: C07K7/08 , A61K38/00 , A61K38/10 , A61K45/06 , C07K14/4703 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
9.发明授权公开(公告)号：US09879046B2
公开(公告)日：2018-01-30
申请号：US15204627
申请日：2016-07-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Li-Qiang Sun , Kap-Sun Yeung , Patrick C. Reid , Paul Michael Scola
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
10.发明授权公开(公告)号：US09850283B2
公开(公告)日：2017-12-26
申请号：US15009575
申请日：2016-01-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
IPC: C07K7/56 , A61K38/12 , C07K7/08 , G01N33/68 , A61K38/10 , A61K39/39 , A61K45/06 , G01N33/574 , A61K38/00
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.046 seconds)
